Urges Stockholders to Elect the Company’s Highly-Qualified Directors on the WHITE Proxy Card at the
The Board of Directors (the "Board") appreciates your continued investment in
We are writing to you today to once again urge you to vote to re-elect all five members of the Board at the Company’s upcoming Annual Meeting of Stockholders (the “Annual Meeting”) on
Support the ongoing
Food and Drug Administration(“FDA”) review of our ZIMHI™ New Drug Application.
- Advance our Phase 2/3 trial for examining the effects of Tempol on COVID-19.
- Support ongoing efforts to obtain government funding for Tempol.
- Advance the Investigational New Drug for Tempol’s use in radiation dermatitis.
- Demonstrate a further increase in SYMJEPI® sales.
- Maintain a strong capital position and healthy balance sheet.
- Prioritize progress across our entire product pipeline.
Based on our decades of collective experience in the biotechnology and pharmaceutical sectors, we firmly believe that Adamis is nearing a promising inflection point. We contend it is not the time to deviate from these priorities. The progress we are beginning to catalyze for SYMJEPI®, ZIMHI™ and now Tempol stems from months and years of planning and work. This is the time to remain focused on – not pull back from – the efforts we are undertaking.
We urge stockholders not to be misled for a number of reasons, including:
Mr. Hammanninitially demanded a lucrative and unjusitified paid consulting agreement – which would have been paid for with stockholders’ capital – before he was even a stockholder of the Company.
Mr. Hammannthreatened to make books and records demands and to run a campaign against the Board if we did not quickly agree to award him the demanded consulting agreement.
Mr. Hammannhas no operating experience in the biotechnology or pharmaceutical sector.
Mr. Hammannhas no experience as a director or executive of a public company.
Mr. Hammannhas a history of filing serial lawsuits and being a vexatious litigator.
Mr. Hammannsubmitted an untimely and invalid notice of director nominations. His nominations will not be accepted at the Annual Meeting.
Mr. Hammannunsuccessfully sued the Company in an attempt to delay the Annual Meeting and forced us to expend precious stockholder capital on fending off litigation.
Mr. Hammannhas no plan for the Company.
We hope stockholders recognize that supporting Mr. Hammann’s misguided campaign would be akin to taking what we believe is a major risk. Rather than support a litigious stockholder that is waging a costly and distracting battle with the Company, we urge you to reject his efforts by voting to re-elect your current Board.
Once again, we thank you for your investment in Adamis. We firmly believe that the Company is on the right path now that we have tangible pipeline momentum. Vote on the WHITE proxy card to elect our full five-member slate and help us sustain the Company’s progress.
The Adamis Board of Directors
PROTECT YOUR INVESTMENT IN ADAMIS – PLEASE SIGN, DATE AND PROMPTLY RETURN THE WHITE PROXY CARD.
The Board urges you to carefully consider the information contained in the Company’s proxy materials and cast your vote on the WHITE proxy card.
DO NOT download any blue proxy card provided by
Jerald A. Hammann.
DO NOT return any blue proxy card to
Jerald A. Hammanneven as a protest vote against his campaign.
DO NOT respond to any email or phone solicitations from
Jerald A. Hammann.
CONTACT THE COMPANY’S PROXY SOLICITOR AT INFO@SARATOGAPROXY.COM OR (888) 368-0379 IF YOU HAVE ANY QUESTIONS REGARDING THE ANNUAL MEETING OR HOW TO VOTE.
Forward Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include those that express plans, anticipation, intent, contingencies, goals, targets or future development and/or otherwise are not statements of historical fact. These statements relate to future events or future results of operations, including, but not limited to the following statements: the Company’s beliefs concerning the safety and effectiveness of Tempol and the Company’s other product candidates; the timing of commencement or completion of any studies or trials relating to Tempol and the availability of funding for studies or trials; the results of any studies or trials that the Company may conduct relating to Tempol; the Company’s ability to successfully commercialize the products and product candidates described in this press release, itself or through commercialization partners, and the Company’s beliefs concerning the commercial success of its products; future regulatory actions relating to the Company’s New Drug Application (“NDA”) relating to its ZIMHI product; the Company’s beliefs concerning the benefits, enforceability, and extent of intellectual property protection afforded by patents and patent applications that it owns or has licensed and its rights under applicable license agreements, and its ability to enforce its patents and other intellectual property rights against third parties; the Company’s expectations concerning future growth; expectations and statements about the Company’s strategies, objectives, future goals and achievements; and other statements concerning our future operations, activities and financial results. These statements are only predictions and involve known and unknown risks, uncertainties, and other factors, which may cause Adamis’ actual results to be materially different from the results anticipated by such forward-looking statements. There can be no assurances regarding the outcome of trials or studies relating to Tempol or that Tempol will be found to be safe and effective in the treatment of COVID-19 or any other indication. There can be no assurances that future sales of SYMJEPI will meet our expectations. There can be no assurances regarding the timing or outcome of the FDA’s review of our resubmitted NDA relating to ZIMHI, or that the Company will be able to successfully take any actions or develop any additional information that the FDA may require in connection with its review of the resubmitted NDA for ZIMHI. There can be no assurances that the FDA will consider the Company’s responses included in the resubmitted NDA relating to ZIMHI as satisfactory, or that the product will be able to compete successfully in the market if approved and launched. The Company may not achieve one or more of the future goals described in the press release either within the anticipated time periods or at all. In addition, as previously disclosed, each of the Company and